25.06.2015 - German immunotherapy expert BioNTech AG has partnered up with Europe’s largest engineering company Siemens to construct a manufacturing site for BioNTech’s personalised cancer vaccine.
The strategic collaboration between the companies aims to optimise automation and digitalisation technology for a commercial-scale GMP production of personalised medicines. BioNTech AG’s subsidiaries, BioNTech RNA Pharmaceuticals GmbH and EUFETS GmbH, will work together with Siemens to construct a fully automated and digitalized production site. At the site, BioNTech plans to manufacture its Ivac individualised cancer vaccines at a large scale. The company’s Ivac Mutanome immunotherapy is engineered on demand and targets the unique mutation signature of an individual patient’s tumour. It is currently in a Phase I/IIa clinical trial for the treatment of malignant melanoma. Once approved, the vaccine would be custom-designed, manufactured and distributed for each individual patient.
“The development and manufacturing of personalised medicine is connected with massive amounts of data. Solutions such as our manufacturing operations management software are able to handle the complexity of this innovative new process technology,” commented Eckard Eberle, CEO of the Siemens Business Unit Process Automation. “Together with BioNTech’s competence in individualised medicine, we will pave the way for a digital plant with an efficient and completely paperless production.”
24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.
22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.
12.06.2015 The high-potential cancer immunotherapy market is fiercely fought, and small companies have trouble making their mark. Nordic companies Targovax and Oncos have joined forces to create a Nordic immuno-oncology champion named Polaris.
05.06.2015 Polish drug maker Polpharma has received a €45m loan from the European Investment Bank to further its biosimilar research. The operation is part of InnovFin, a new programme set up to support innovative research.